Phathom Revenue Jumps 71% to $84.7 Million, Target Posts Similar 5.6% Growth
Key Facts
Phathom Pharmaceuticals reported net revenue of $84.7 million in the third quarter of 2026, up 71% year over year and 14% from the second quarter, according to a company statement. The figures reflect broader sales of VOQUEZNA, with total prescriptions dispensed for the drug exceeding two million from launch through October 16. At Target, comparable sales rose 5.6% during the quarter, driven by a 5.0% increase in comparable traffic, the company said. The results put the two companies on different paths: accelerating commercial expansion at the drugmaker and improved sales and visits at the retailer ahead of the holiday season. Target’s results also showed that some of the improvement in earnings per share was tied to tariff refund benefits.
Phathom said about 380,000 VOQUEZNA prescriptions were dispensed in the third quarter alone, part of more than two million since launch. In a move aimed at expanding patients’ access to treatment, the company said eligible patients with commercial insurance may pay $0 through pharmacy partner BlinkRx. The initiative reflects the company’s efforts to support access to the drug alongside prescription growth. But commercial expansion did not eliminate the GAAP loss; Phathom recorded a net loss of $13.9 million, compared with a loss of $30.0 million in the third quarter of 2025. On an adjusted, non-GAAP basis, the company posted net income of $3.0 million in the current quarter.
Phathom had $184.6 million in cash and cash equivalents on September 30, an increase of $2.1 million from the end of the second quarter on June 30. The company maintained its 2026 revenue outlook of $310 million to $325 million, with a gross margin of about 80%. On the drug-development front, Phathom expects to announce topline results in the fourth quarter of 2026 for the 12-week blinded treatment portion of its Phase 2 trial in patients with eosinophilic esophagitis. It also expects topline results from a Phase 3 study of as-needed VOQUEZNA for non-erosive gastroesophageal reflux disease in the first quarter of 2028. These upcoming milestones link current prescription growth to the drug’s clinical path.
On the retail side, Target’s comparable store sales rose 4.6%, while comparable digital sales increased 9.8% in the third quarter. The Fun 101 category grew about 27% year over year, beauty sales rose more than 9%, and food and beverage sales increased about 7%. The company said sales grew in all three months, with the strongest performance during the back-to-school and back-to-college seasons. It added that two-year sales and traffic growth accelerated compared with the first half. Non-merchandise sales also rose about 20%, supported by advertising revenue from Roundel, Target Circle Card profit sharing, Target Circle 360 memberships and the Target+ marketplace.
Target’s gross margin was 30.5%, up 2.3 percentage points from a year earlier, with tariff refunds contributing about 1.1 percentage points to the expansion. GAAP and adjusted earnings per share were $2.65, including a $0.50-per-share benefit from tariff refunds. Target said that excluding the effect of the refunds, GAAP earnings per share would have risen 42% year over year, while adjusted earnings per share would have increased 21%. The reported profitability figure therefore includes an effect from tariff refunds alongside improved operating indicators. Chief Executive Michael Fiddelke said the quarterly results reflect “continued progress on our strategic priorities.”
Target raised its annual sales growth forecast to about 6% and set a fiscal 2026 earnings-per-share range of $10.65 to $11.40, including about $2.14 per share in tariff refund benefits recognized through November 18. The company said November sales through the results announcement were in line with its guidance and expectations, and accelerated compared with October trends. It also forecast capital spending of $5 billion to $6 billion in 2027. Target shares rose 5% at the opening bell on November 18, according to the Associated Press. The move comes as the company prepares for the holiday season, with sales and traffic continuing to grow during the quarter.